• Users Online: 372
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
Year : 2013  |  Volume : 4  |  Issue : 3  |  Page : 89-95

Development of ruxolitinib as a myelofibrosis therapy

1 Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX USA
2 King Khalid University Hospital, King Saud University, Riyadh, Saudi Arabia

Correspondence Address:
Srdan Verstovsek
Department of Leukemia, University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Suite 428, Houston, TX 77030, USA

Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/1658-5127.123299

Rights and Permissions

Myelofibrosis (MF) is a hematologic malignancy characterized by proliferation of an aberrant myeloid-derived stem cell clone, leading to inefficient hematopoiesis and bone marrow fibrosis. Typical clinical manifestations include progressive anemia and splenomegaly, which leads to several debilitating symptoms, including fatigue, night sweats, itching, appetite loss, and bone pain. Janus kinase (JAK)-signal transducer and activator of transcription (STAT) pathway dysregulation is a common feature of MF. Ruxolitinib, an oral JAK1/JAK2 inhibitor, was recently approved by the US Food and Drug Administration and European Medicines Agency for the treatment of MF patients. In clinical trials, patients treated with ruxolitinib had significant reductions in spleen size and improvements in their constitutional symptoms and quality of life (QoL), with possibly prolonged survival. The most common adverse events were anemia and thrombocytopenia. Here, we review the most recent clinical data on ruxolitinib and discuss its use in MF patients.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded271    
    Comments [Add]    

Recommend this journal